Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.59 |
| ▸ | NPC1 | O15118 | 8/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.59 |
| ▸ | LMNA | P02545 | 6/20 | 0.59 |
| ▸ | PKM | P14618 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 7/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.57 |
| ▸ | HTT | P42858 | 3/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29839704 | 1.00 | RAB9A (0.59) | RAB9ANPC1KDM4ELMNAPKM | |
| SCHEMBL372118 | 1.00 | RAB9A (0.59) | RAB9ANPC1KDM4ELMNAPKM | |
| SCHEMBL28443608 | 0.83 | RAB9A (0.80) | RAB9ANPC1KDM4ELMNAPKM | |
| SCHEMBL709664 | 0.81 | NPC1 (0.56) | RAB9ANPC1KDM4ELMNAPKM | |
| SCHEMBL709663 | 0.81 | NPC1 (0.56) | RAB9ANPC1KDM4ELMNAPKM | |
| SCHEMBL230838 | 0.79 | NPC1 (0.57) | RAB9ANPC1KDM4ELMNAPKM | |
| SCHEMBL714134 | 0.79 | RAB9A (0.79) | RAB9ANPC1KDM4ELMNAPKM | |
| SCHEMBL714135 | 0.79 | RAB9A (0.79) | RAB9ANPC1KDM4ELMNAPKM | |
| SCHEMBL5099515 | 0.78 | RAB9A (0.66) | RAB9ANPC1KDM4ELMNAPKM | |
| SCHEMBL5099524 | 0.78 | RAB9A (0.66) | RAB9ANPC1KDM4ELMNAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071620-B2 | Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-8071620-B2 | Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-8071620-B2 | Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2011-12-06 | — | — | US | disclosed |
| US-20100093743-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A BICYCLIC HETEROARYL GROUP AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100093743-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A BICYCLIC HETEROARYL GROUP AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-20100093743-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A BICYCLIC HETEROARYL GROUP AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
| US-7652036-B2 | Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2010-01-26 | — | — | US | disclosed |
| US-7652036-B2 | Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2010-01-26 | — | — | US | disclosed |
| US-7652036-B2 | Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2010-01-26 | — | — | US | disclosed |
| US-7342026-B2 | Substituted quinolines for the treatment of protozoa and retrovirus co-infections | INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT (FR) | 2008-03-11 | — | — | US | disclosed |
| EP-1599449-A2 | CARBAMIC ACID COMPOUNDS COMPRISING A BICYCLIC HETEROARYL GROUP AS HDAC INHIBITORS | TopoTarget UK Limited (GB) | 2005-11-30 | — | — | EP | disclosed |
| US-20050165052-A1 | Substituted quinolines for the treatment of protozoa and retrovirus co-infections | INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT (FR) | 2005-07-28 | — | — | US | disclosed |
| WO-2004076386-A2 | CARBAMIC ACID COMPOUNDS COMPRISING A BICYCLIC HETEROARYL GROUP AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2004-09-10 | — | — | WO | disclosed |
| EP-1351940-A1 | SUBSTITUTED QUINOLINES FOR THE TREATMENT OF PROTOZOAN AND RETROVIRUS CO-INFECTIONS | Institut de Recherche pour le Développement ( IRD) (FR) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002057238-A1 | SUBSTITUTED QUINOLINES FOR THE TREATMENT OF PROTOZOAN AND RETROVIRUS CO-INFECTIONS | INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT (IRD) (FR) | 2002-07-25 | — | — | WO | disclosed |
| EP-0771796-B1 | Substituted S-triazines and process for their preparation | AGFA GEVAERT (BE) | 2002-06-19 | — | — | EP | disclosed |
| US-6025390-A | Heteroaromatic pentadienoic acid derivatives useful as inhibitors of bone resorption | SMITHKLINE BEECHAM SPA (IT) | 2000-02-15 | — | — | US | disclosed |
| EP-0912539-A1 | HETEROAROMATIC PENTADIENOIC ACID DERIVATIVES USEFUL AS INHIBITORS OF BONE RESORPTION | Smithkline Beecham S.p.A. (IT) | 1999-05-06 | — | — | EP | disclosed |
| WO-1998001436-A1 | HETEROAROMATIC PENTADIENOIC ACID DERIVATIVES USEFUL AS INHIBITORS OF BONE RESORPTION | SMITHKLINE BEECHAM S.P.A. (IT) | 1998-01-15 | — | — | WO | disclosed |
| EP-0771796-A1 | Substituted S-triazines and process for their preparation | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165052-A1 | Substituted quinolines for the treatment of protozoa and retrovirus co-infections | C1S, C5, NSFL1C | RAB9A 1036/4885NPC1 242/4885KDM4E 3607/4885 |
| US-20100093743-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A BICYCLIC HETEROARYL GROUP AS HDAC INHIBITORS | HDAC1, HDAC7, HDAC5 | RAB9A 1482/4885NPC1 1468/4885KDM4E 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.